Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: LACI; SC 59735; TFP561; TFPI - Chiron/Pfizer; Tissue factor pathway inhibitor - Chiron/Pfizer

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiron
  • Developer Novartis
  • Class Antithrombotics; Biological proteins
  • Mechanism of Action Factor Xa inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Community-acquired pneumonia; Reperfusion injury; Septic shock; Thrombosis

Most Recent Events

  • 28 Jan 2009 Development discontinued for Community-acquired pneumonia during 2008
  • 22 Apr 2008 Pharmacodynamics data from a preclinical trial against Escherichia coli infection (related to Community-acquired pneumonia) presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2008)
  • 22 May 2007 Tifacogin is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top